Day: May 15, 2025

Amsterdam, May 15, 2025 HighlightsYear-to-date Directional1 revenue of US$1,103 million, up 27% versus 1Q 2024 Full year 2025 Directional revenue and EBITDA guidance maintained Cash dividend of EUR150 million (equivalent to EUR0.8606 per ordinary share) paid on May 6, 2025 EUR141 million share repurchase program on track, c. 6.75% completed2 First oil for FPSO Almirante Tamandaré, FPSOs Alexandre de Gusmão & ONE GUYANA on track for first oil Strategic Collaboration Agreement signed with Microsoft to develop carbon-free floating power solutions Completion of the US$400 million sale and leaseback transaction for FPSO Cidade de Paraty Refinancing and increase to US$1.1 billion of the unsecured revolving credit facilityØivind Tangen, CEO of SBM Offshore, commented: “Our first quarter results, along with our full year Directional revenue...

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) — Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok. These events reflect Anbio’s strategic commitment to expanding its global footprint across human and animal healthcare, building new partnerships, and sharing its vision for accessible, high-performance diagnostics. As healthcare systems around the world seek faster, more accurate, and decentralized testing solutions, Anbio is well-positioned to meet this demand through a diversified portfolio and expanding global network. “These...

On May 14, J&T Finance Group SE, based in the Czech Republic and the majority shareholder of 365.bank a.s. and KBC Bank NV reached an agreement for KBC to acquire a 98.45% stake in 365.bank (in cash), based on a total value for 365.bank of EUR 761 million. The transaction is subject to relevant regulatory and anti-trust approvals and is expected to close by the end of this year. 365.bank, a commercial bank in Slovakia, holds a 3.7% market share by assets as of December 20241 with a notable strength in retail banking. Acquiring 365.bank would strengthen KBC in Slovakia ensuring KBC’s reference status across all Central and Eastern European countries of presence. The transaction price represents a 1.4x multiple of the December 2024 book value of 365.bank and a 9.4x P/E based on the average net profit of 365.bank from 2022 to 2024....

KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update. “As part of the Company’s efforts to reduce operating costs it has determined to focus on the development of the plogosertib (“plogo”) clinical program only. Accordingly, on March 10, 2025, the Company repurchased certain assets related to plogo from Cyclacel Limited for approximately $0.3 million in cash, to allow us to continue our efforts on developing an alternative salt, oral formulation of plogosertib with improved bioavailability,” said Datuk Dr. Doris Wong, Chief Executive Officer. “Cyclacel Limited’s other drug...

HONG KONG, May 14, 2025 (GLOBE NEWSWIRE) — Primega Group Holdings Limited (Nasdaq: PGHL) today announced that its ticker symbol on the Nasdaq Stock Market will be changed from “PGHL” to “ZDAI”, effective May 16, 2025. This change reflects Primega Group Holdings Limited’s evolving identity and strategic vision as it continues to expand its presence in the market. The new ticker symbol, “ZDAI”, symbolizes the company’s commitment to innovation, growth, and excellence in all its endeavors. Building upon its existing business, Primega Group Holdings Limited is set to venture into groundbreaking territories, focusing on technological advancements in hotel marketing software development, digitized supply chain platforms, AI and IoT integration, cloud computing, and intelligent engineering...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity means that the FDA will not approve another mesenchymal stromal or stem cell (MSC) products for this indication during the 7-year period from the approval of Ryoncil®. Separately, Mesoblast has biologic exclusivity preventing another sponsor from referencing the Ryoncil® biologic license application (BLA) until December 2036, twelve years from its first approval which...

PHOENIX, May 14, 2025 (GLOBE NEWSWIRE) — Cavco Industries, Inc. (Nasdaq: CVCO) will release earnings for the fourth quarter and fiscal year ended March 29, 2025 on Thursday, May 22, 2025 after the close of market. Senior management will discuss the results in a live webcast the following day, Friday, May 23, 2025 at 10:00 a.m. Eastern Time. Date:   May 23, 2025 Time:   10:00 a.m. ET            Listen via Internet: https://investor.cavco.com/ Listen via Telephone: To participate in the call, please register here to receive the dial-in number and your unique PIN. If you are unable to participate during the live webcast, the call will be available for 60 days on https://investor.cavco.com/. Cavco Industries, Inc., headquartered in Phoenix, Arizona, designs and produces factory-built housing products primarily distributed through a...